About the company
Neurocrine Biosciences Inc is a pioneering research-based pharmaceutical company at the forefront of advancing potentially life-changing drug candidates in the field of the central nervous system (CNS) and endocrine-related diseases. By utilizing cutting-edge scientific research and innovative approaches, Neurocrine Biosciences is committed to developing novel therapies to address unmet medical needs and improve the lives of patients around the world. One of the key areas of focus for Neurocrine Biosciences is women's health. The company's flagship late-stage clinical program in this category is elagolix, a hormone-releasing antagonist. Elagolix is being developed to address the debilitating symptoms of various gynecological disorders, including endometriosis and uterine fibroids. By selectively targeting and blocking the production of certain hormones, elagolix has the potential to significantly reduce pain and improve the quality of life for millions of women suffering from these conditions. In the realm of Parkinson's disease, Neurocrine Biosciences is making noteworthy progress with opicapone, a highly selective COMT inhibitor. Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and subsequent motor impairments. Opicapone is designed to prolong the effects of existing treatments for Parkinson's disease by inhibiting the enzyme responsible for the breakdown of dopamine. By enhancing the availability of dopamine, opicapone may help manage the motor symptoms associated with the disease and enhance patients' overall well-being. Another promising late-stage clinical program by Neurocrine Biosciences is focused on addressing Tourette syndrome, a neurodevelopmental disorder characterized by repetitive, involuntary movements and vocalizations known as tics. Ingrezza, the company's highly innovative therapeutic candidate, is the first FDA-approved treatment specifically indicated for adults with this challenging condition. Ingrezza acts by selectively inhibiting the release of dopamine in specific regions of the brain, thereby reducing the frequency and severity of tics. This breakthrough therapy has shown remarkable efficacy in clinical trials and has the potential to significantly improve the lives of individuals living with Tourette syndrome. Neurocrine Biosciences is committed to not only developing innovative therapies but also to ensuring their accessibility to patients who need them the most. With a patient-centered approach, the company collaborates closely with medical professionals, patient advocacy groups, and regulatory authorities to ensure that its drug candidates are thoroughly evaluated, rigorously tested, and ultimately approved with a high degree of safety and efficacy. Furthermore, Neurocrine Biosciences actively engages in ongoing research and development activities to explore new therapeutic areas and pursue opportunities to further expand its pipeline. By leveraging its expertise in neuroscience, endocrinology, and drug development, the company aims to discover and develop novel therapies that can address the underlying causes of various CNS and endocrine-related diseases. As Neurocrine Biosciences continues to push the boundaries of scientific innovation, it remains dedicated to improving the lives of patients worldwide by delivering breakthrough treatments in the field of CNS and endocrine-related diseases. Through its commitment to excellence and patient-centric approach, the company is poised to make significant contributions to the advancement of medical science and the well-being of patients for years to come.
Website: https://www.neurocrine.com
Data updated: June 2, 2026
